HEADER RIBOSOME/ANTIBIOTIC 08-AUG-03 1OLN TITLE MODEL FOR THIOSTREPTON ANTIBIOTIC BINDING TO L11 SUBSTRATE FROM 50S TITLE 2 RIBOSOMAL RNA COMPND MOL_ID: 1; COMPND 2 MOLECULE: 50S RIBOSOMAL PROTEIN L11; COMPND 3 CHAIN: A; COMPND 4 MOL_ID: 2; COMPND 5 MOLECULE: THIOSTREPTON; COMPND 6 CHAIN: B; COMPND 7 SYNONYM: ALANINAMIDE, BRYAMYCIN, THIACTIN; COMPND 8 MOL_ID: 3; COMPND 9 MOLECULE: RNA; COMPND 10 CHAIN: C; COMPND 11 FRAGMENT: RESIDUES 1051-1108 SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: THERMOTOGA MARITIMA; SOURCE 3 ORGANISM_TAXID: 2336; SOURCE 4 MOL_ID: 2; SOURCE 5 ORGANISM_SCIENTIFIC: STREPTOMYCES AZUREUS; SOURCE 6 ORGANISM_TAXID: 146537; SOURCE 7 MOL_ID: 3; SOURCE 8 ORGANISM_SCIENTIFIC: THERMOTOGA MARITIMA; SOURCE 9 ORGANISM_TAXID: 2336 KEYWDS RIBOSOME-ANTIBIOTIC COMPLEX, THIOPEPTIDE, ANTIBACTERIAL, THIAZOLE, KEYWDS 2 OXAZOLE, RIBOSOME, L11, TRANSLATION INHIBITION EXPDTA SOLUTION NMR; THEORETICAL MODEL MDLTYP MINIMIZED AVERAGE AUTHOR G.LENTZEN,R.KLINCK,N.MATASSOVA,F.ABOUL-ELA,A.I.H.MURCHIE REVDAT 6 21-AUG-19 1OLN 1 REMARK REVDAT 5 24-APR-19 1OLN 1 SEQRES LINK REVDAT 4 15-NOV-17 1OLN 1 REMARK REVDAT 3 13-JUL-11 1OLN 1 VERSN REVDAT 2 24-FEB-09 1OLN 1 VERSN REVDAT 1 11-SEP-03 1OLN 0 JRNL AUTH G.LENTZEN,R.KLINCK,N.MATASSOVA,F.ABOUL-ELA,A.I.H.MURCHIE JRNL TITL STRUCTURAL BASIS FOR CONTRASTING ACTIVITIES OF RIBOSOME JRNL TITL 2 BINDING THIAZOLE ANTIBIOTICS JRNL REF CHEM.BIOL. V. 10 769 2003 JRNL REFN ISSN 1074-5521 JRNL PMID 12954336 JRNL DOI 10.1016/S1074-5521(03)00173-X REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH B.T.WIMBERLY,R.GUYMON,J.P.MCCUTCHEON,S.W.WHITE, REMARK 1 AUTH 2 V.RAMAKRISHNAN REMARK 1 TITL A DETAILED VIEW OF A RIBOSOMAL ACTIVE SITE: THE STRUCTURE OF REMARK 1 TITL 2 THE L11-RNA COMPLEX REMARK 1 REF CELL(CAMBRIDGE,MASS.) V. 97 491 1999 REMARK 1 REFN ISSN 0092-8674 REMARK 1 PMID 10338213 REMARK 1 DOI 10.1016/S0092-8674(00)80759-X REMARK 1 REFERENCE 2 REMARK 1 AUTH G.L.CONN,D.E.DRAPER,E.E.LATTMAN,A.G.GITTIS REMARK 1 TITL CRYSTAL STRUCTURE OF A CONSERVED RIBOSOMAL PROTEIN-RNA REMARK 1 TITL 2 COMPLEX REMARK 1 REF SCIENCE V. 284 1171 1999 REMARK 1 REFN ISSN 0036-8075 REMARK 1 PMID 10325228 REMARK 1 DOI 10.1126/SCIENCE.284.5417.1171 REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : RDOCK REMARK 3 AUTHORS : DAVID MORLEY REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: THE COORDINATES OF THE PROTEIN, RNA AND REMARK 3 THE ANTIBIOTIC WERE HELD RIGID DURING REFINEMENT. THE REMARK 3 COORDINATES OF THE RIBOSOMAL L11 (CHAIN A) AND THE RNA (CHAIN C) REMARK 3 WERE FROM PDB ENTRY 1MMS. THE COORDINATES OF THE ANTIBIOTIC REMARK 3 THIOSTREPTON (CHAIN B) WERE FROM PDB ENTRY 1E9W. REFINEMENT REMARK 3 DETAILS CAN BE FOUND IN THE JRNL CITATION. REMARK 4 REMARK 4 1OLN COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 08-AUG-03. REMARK 100 THE DEPOSITION ID IS D_1290013289. REMARK 210 REMARK 210 EXPERIMENTAL DETAILS REMARK 210 EXPERIMENT TYPE : NMR REMARK 210 TEMPERATURE (KELVIN) : 303 REMARK 210 PH : 6.2 REMARK 210 IONIC STRENGTH : 100 MM NACL, 5 MM MGCL2 REMARK 210 PRESSURE : 1 ATM REMARK 210 SAMPLE CONTENTS : NULL REMARK 210 REMARK 210 NMR EXPERIMENTS CONDUCTED : NOESY REMARK 210 SPECTROMETER FIELD STRENGTH : 600 MHZ REMARK 210 SPECTROMETER MODEL : DRX REMARK 210 SPECTROMETER MANUFACTURER : BRUKER REMARK 210 REMARK 210 STRUCTURE DETERMINATION. REMARK 210 SOFTWARE USED : NULL REMARK 210 METHOD USED : DOCKING/MODELING REMARK 210 REMARK 210 CONFORMERS, NUMBER CALCULATED : NULL REMARK 210 CONFORMERS, NUMBER SUBMITTED : 1 REMARK 210 CONFORMERS, SELECTION CRITERIA : LEAST RESTRAINT VIOLATION AND REMARK 210 BEST OVERALL DOCKING SCORE REMARK 210 REMARK 210 BEST REPRESENTATIVE CONFORMER IN THIS ENSEMBLE : NULL REMARK 210 REMARK 210 REMARK: BEST OVERALL DOCKING SCORE AND LEAST RESTRAINT VIOLATION. REMARK 210 THE NOES INCLUDED IN THE RESTRAINTED MODELING WERE OBTAINED FROM REMARK 210 A FILTERED NOESY EXPERIMENT ON A COMPLEX OF UNLABELED REMARK 210 THIOSTREPTON WITH THE RNA. AS ALL INTERNAL COORDINATES WERE HELD REMARK 210 RIGID ACCORDING TO THE X-RAY STRUCTURES, ONLY INTERMOLECULAR REMARK 210 NOES WERE INCLUDED. ASSIGNMENTS FOR RNA WERE CHOSEN FROM AN REMARK 210 ITERATIVE DOCKING PROCESS (SEE LENTZEN ET AL AND MANUSCRIPT TO REMARK 210 BE PUBLISHED) REMARK 215 REMARK 215 NMR STUDY REMARK 215 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM SOLUTION REMARK 215 NMR DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE THAT REMARK 215 CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES ON REMARK 215 THESE RECORDS ARE MEANINGLESS. REMARK 220 REMARK 220 EXPERIMENTAL DETAILS REMARK 220 EXPERIMENT TYPE : THEORETICAL MODELLING REMARK 220 REMARK 220 REMARK: THIS THEORETICAL MODEL ENTRY WAS NOT ANNOTATED AND NOT REMARK 220 VALIDATED BY THE WWPDB STAFF AND THEREFORE MAY NOT CONFORM REMARK 220 TO THE PDB FORMAT. REMARK 225 REMARK 225 THEORETICAL MODEL REMARK 225 THE COORDINATES IN THIS ENTRY REPRESENT A MODEL STRUCTURE. REMARK 225 PROTEIN DATA BANK CONVENTIONS REQUIRE THAT CRYST1 AND REMARK 225 SCALE RECORDS BE INCLUDED, BUT THE VALUES ON THESE REMARK 225 RECORDS ARE MEANINGLESS. REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TRIMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B, C REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 THIOSTREPTON IS A MEMBER OF A SULPHUR-RICH HETEROCYCLIC PEPTIDES REMARK 400 CLASS. ALL SHARE A MACROCYLIC CORE, CONSISTING OF A REMARK 400 NITROGEN CONTAINING, SIX-MEMBERED RING CENTRAL TO DEHYDROAMINO REMARK 400 ACIDS AND A SUBSET OF FIVE MEMBER RING STRUCTURES INCLUDING REMARK 400 THIAZOLES, THIAZOLINES AND OXAZOLES. REMARK 400 HERE, THIOSTREPTON IS REPRESENTED BY THE SEQUENCE (SEQRES) REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: THIOSTREPTON REMARK 400 CHAIN: B REMARK 400 COMPONENT_1: PEPTIDE LIKE SEQUENCE RESIDUES 0 TO 18 REMARK 400 DESCRIPTION: THIOSTREPTON IS A HETEROCYCLIC THIOPEPTIDE, REMARK 400 CONSISTING OF FOUR THIAZOLES ONE THIAZOLINE REMARK 400 ONE PIPERIDEINE RINGS. REMARK 400 A MODIFIED QUINOLINE LINKED TO MAIN-CHAIN REMARK 400 RESIDUE 1 AND SIDE-CHAIN OF RESIDUE 12. REMARK 400 THE OBSERVED C-TERMINAL AMINO GROUP NH2(18) IS REMARK 400 LIKELY TO BE A POST-TRANSLATIONAL DECARBOXYLATED REMARK 400 REMNANT OF A SER C-TERMINAL RESIDUE. REMARK 400 REMARK 400 THE THIOSTREPTON IS THIOPEPTIDE, A MEMBER OF ANTIBIOTIC CLASS. REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: THIOSTREPTON REMARK 400 CHAIN: B REMARK 400 COMPONENT_1: PEPTIDE LIKE POLYMER REMARK 400 DESCRIPTION: Thiostrepton is a hetrocyclic thiopeptide belonging REMARK 400 to the thiocillin family, consisting of four REMARK 400 thiazole, one thiozoline and one piperideine rings. REMARK 400 A modified quinoline linked to main-chain residue 1 REMARK 400 and side-chain of residue 12. Post translational REMARK 400 maturation of thiazole and oxazole containing REMARK 400 antibiotics involves the enzymic condensation of a REMARK 400 Cys or Ser with the alpha-carbonyl of the preceding REMARK 400 amino acid to form a thioether or ether bond, then REMARK 400 dehydration to form a double bond with the alpha- REMARK 400 amino nitrogen. Thiazoline or oxazoline ring are REMARK 400 dehydrogenated to form thiazole or oxazole rings. REMARK 400 the pyridinyl involves the cross-linking of a Ser REMARK 400 and a Cys-Ser pair usually separated by 7 or 8 REMARK 400 residues along the peptide chain. The Ser residues REMARK 400 are dehydrated to didehydroalanines, then bonded REMARK 400 between their beta carbons. The alpha carbonyl of REMARK 400 the Cys condenses with alpha carbon of the first Ser REMARK 400 to form a pyridinyl ring. The ring may be mutiply REMARK 400 dehydrogenated to form a pyridine ring with loss of REMARK 400 the amino nitrogen of the first Ser. The amidation REMARK 400 of Ser-17 probably does not occur by the same REMARK 400 mechanism, oxidative cleavage of glycine, as in REMARK 400 eukaryotes. REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 465 SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 RES C SSSEQI REMARK 465 ALA A 2 REMARK 465 LYS A 3 REMARK 465 LYS A 4 REMARK 465 VAL A 5 REMARK 465 ALA A 6 REMARK 465 ALA A 7 REMARK 465 ASP A 141 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND LENGTHS REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,2(A3,1X,A1,I4,A1,1X,A4,3X),1X,F6.3) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 RES CSSEQI ATM2 DEVIATION REMARK 500 BB9 B 13 C MH6 B 14 N 0.138 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ALA A 15 -99.29 -38.18 REMARK 500 LYS A 17 140.91 -176.59 REMARK 500 THR A 19 -25.33 95.17 REMARK 500 VAL A 24 -92.82 -94.06 REMARK 500 PRO A 26 -52.70 -28.71 REMARK 500 ALA A 27 -89.24 -39.55 REMARK 500 ILE A 35 -73.68 -27.29 REMARK 500 GLU A 62 -34.92 -34.81 REMARK 500 LYS A 64 -9.28 68.48 REMARK 500 LYS A 93 -42.99 75.48 REMARK 500 SER B 5 80.85 71.83 REMARK 500 DCY B 9 -14.72 -147.29 REMARK 500 TS9 B 10 -65.50 -107.46 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: PLANAR GROUPS REMARK 500 REMARK 500 PLANAR GROUPS IN THE FOLLOWING RESIDUES HAVE A TOTAL REMARK 500 RMS DISTANCE OF ALL ATOMS FROM THE BEST-FIT PLANE REMARK 500 BY MORE THAN AN EXPECTED VALUE OF 6*RMSD, WITH AN REMARK 500 RMSD 0.02 ANGSTROMS, OR AT LEAST ONE ATOM HAS REMARK 500 AN RMSD GREATER THAN THIS VALUE REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 M RES CSSEQI RMS TYPE REMARK 500 A C1069 0.06 SIDE CHAIN REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN B OF THIOSTREPTON REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1D8T RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE ELONGATION FACTOR EF-TU-MGGDP COMPLEXED REMARK 900 WITH THE THIOPEPTIDE GE2270A. REMARK 900 RELATED ID: 1E9W RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THIOPEPTIDE THIOSTREPTON REMARK 900 RELATED ID: 2C77 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE ELONGATION FACTOR EF-TU-GNP COMPLEXED WITH REMARK 900 THIOPEPTIDE GE2270A. REMARK 900 RELATED ID: 2JQ7 RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF THE COMPLEX OF THIOPEPTIDE THIOSTREPTON AND REMARK 900 RIBOSOMAL L11-RNA REMARK 900 RELATED ID: 2ZJP RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF NOSIHEPTIDE COMPLEXED WITH THE LARGE RIBOSOMAL REMARK 900 SUBUNIT OF DEINOCOCCUS RADIODURANS REMARK 900 RELATED ID: 3CF5 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF RIBOSOMAL L11-RNA COMPLEXED WITH THE REMARK 900 THIOPEPTIDE THIOSTREPTON REMARK 900 RELATED ID: 1MMS RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE RIBOSOMAL PROTEIN L11-RNA COMPLEX REMARK 900 RELATED ID: 1EG0 RELATED DB: PDB REMARK 900 FITTING OF COMPONENTS WITH KNOWN STRUCTURE INTO AN 11.5 A CRYO-EM REMARK 900 MAP OF THE E. COLI 70S RIBOSOME REMARK 900 RELATED ID: 1GIY RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE RIBOSOME AT 5.5A RESOLUTIO REMARK 900 RELATED ID: 1JQM RELATED DB: PDB REMARK 900 FITTING OF L11 PROTEIN AND ELONGATION FACTOR G (EF-G) IN THE CRYO- REMARK 900 EM MAP OF E. COLI 70S RIBOSOME BOUND WITH EF-G,GDP AND FUSIDIC ACID REMARK 900 RELATED ID: 1JQS RELATED DB: PDB REMARK 900 FITTING OF L11 PROTEIN AND ELONGATION FACTOR G (DOMAIN G'AND V) IN REMARK 900 THE CRYO-EM MAP OF E. COLI 70S RIBOSOME BOUNDWITH EF-G AND GMPPCP REMARK 900 RELATED ID: 1JQT RELATED DB: PDB REMARK 900 FITTING OF L11 PROTEIN IN THE LOW RESOLUTION CRYO-EM MAP OFE.COLI REMARK 900 70S RIBOSOME REMARK 900 RELATED ID: 1PN7 RELATED DB: PDB REMARK 900 COORDINATES OF S12, L11 PROTEINS AND P-TRNA, FROM THE 70S X-RAY REMARK 900 STRUCTURE ALIGNED TO THE 70S CRYO-EM MAP OF E. COLIRIBOSOME REMARK 900 RELATED ID: 1PN8 RELATED DB: PDB REMARK 900 COORDINATES OF S12, L11 PROTEINS AND E-SITE TRNA FROM 70S CRYSTAL REMARK 900 STRUCTURE SEPARATELY FITTED INTO THE CRYO-EM MAPOF E.COLI 70S.EF- REMARK 900 G.GDPNP COMPLEX. THE COORDINATESORIGINALLY FROM THE E-SITE TRNA REMARK 900 WERE FITTED IN THEPOSITION OF THE HYBRID P /E-SITE TRNA. REMARK 900 RELATED ID: 487D RELATED DB: PDB REMARK 900 SEVEN RIBOSOMAL PROTEINS FITTED TO A CRYO-EM MAP OF THE LARGE 50S REMARK 900 SUBUNIT AT 7.5 A. DBREF 1OLN A 2 141 UNP P29395 RL11_THEMA 2 141 DBREF 1OLN B 1 17 UNP P0C8P8 THCL_STRAJ 1 17 DBREF 1OLN C 1051 1108 PDB 1OLN 1OLN 1051 1108 SEQRES 1 A 140 ALA LYS LYS VAL ALA ALA GLN ILE LYS LEU GLN LEU PRO SEQRES 2 A 140 ALA GLY LYS ALA THR PRO ALA PRO PRO VAL GLY PRO ALA SEQRES 3 A 140 LEU GLY GLN HIS GLY VAL ASN ILE MET GLU PHE CYS LYS SEQRES 4 A 140 ARG PHE ASN ALA GLU THR ALA ASP LYS ALA GLY MET ILE SEQRES 5 A 140 LEU PRO VAL VAL ILE THR VAL TYR GLU ASP LYS SER PHE SEQRES 6 A 140 THR PHE ILE ILE LYS THR PRO PRO ALA SER PHE LEU LEU SEQRES 7 A 140 LYS LYS ALA ALA GLY ILE GLU LYS GLY SER SER GLU PRO SEQRES 8 A 140 LYS ARG LYS ILE VAL GLY LYS VAL THR ARG LYS GLN ILE SEQRES 9 A 140 GLU GLU ILE ALA LYS THR LYS MET PRO ASP LEU ASN ALA SEQRES 10 A 140 ASN SER LEU GLU ALA ALA MET LYS ILE ILE GLU GLY THR SEQRES 11 A 140 ALA LYS SER MET GLY ILE GLU VAL VAL ASP SEQRES 1 B 19 QUA ILE ALA DHA ALA SER BB9 THR DBU DCY TS9 BB9 THR SEQRES 2 B 19 BB9 MH6 BB9 DHA DHA NH2 SEQRES 1 C 58 G C U G G G A U G U U G G SEQRES 2 C 58 C U U A G A A G C A G C C SEQRES 3 C 58 A U C A U U U A A A G A G SEQRES 4 C 58 U G C G U A A C A G C U C SEQRES 5 C 58 A C C A G C MODRES 1OLN DHA B 3 SER 2-AMINO-ACRYLIC ACID MODRES 1OLN BB9 B 6 CYS MODRES 1OLN DBU B 8 THR (2Z)-2-AMINOBUT-2-ENOIC ACID MODRES 1OLN TS9 B 10 ILE MODRES 1OLN BB9 B 11 CYS MODRES 1OLN BB9 B 13 CYS MODRES 1OLN MH6 B 14 SER 3-HYDROXY-2-IMINOPROPANOIC ACID MODRES 1OLN BB9 B 15 CYS MODRES 1OLN DHA B 16 SER 2-AMINO-ACRYLIC ACID MODRES 1OLN DHA B 17 SER 2-AMINO-ACRYLIC ACID HET QUA B 0 16 HET DHA B 3 5 HET BB9 B 6 6 HET DBU B 8 5 HET DCY B 9 6 HET TS9 B 10 9 HET BB9 B 11 6 HET BB9 B 13 5 HET MH6 B 14 4 HET BB9 B 15 6 HET DHA B 16 5 HET DHA B 17 5 HET NH2 B 18 1 HETNAM QUA 8-HYDROXY-4-(1-HYDROXYETHYL)QUINOLINE-2-CARBOXYLIC ACID HETNAM DHA 2-AMINO-ACRYLIC ACID HETNAM BB9 (2Z)-2-AMINO-3-SULFANYLPROP-2-ENOIC ACID HETNAM DBU (2Z)-2-AMINOBUT-2-ENOIC ACID HETNAM DCY D-CYSTEINE HETNAM TS9 (2S,3S,4R)-2-AMINO-3,4-DIHYDROXY-3-METHYLPENTANOIC ACID HETNAM MH6 3-HYDROXY-2-IMINOPROPANOIC ACID HETNAM NH2 AMINO GROUP HETSYN DHA 2,3-DIDEHYDROALANINE HETSYN DBU Z-DEHYDROBUTYRINE FORMUL 2 QUA C12 H13 N O4 FORMUL 2 DHA 3(C3 H5 N O2) FORMUL 2 BB9 4(C3 H5 N O2 S) FORMUL 2 DBU C4 H7 N O2 FORMUL 2 DCY C3 H7 N O2 S FORMUL 2 TS9 C6 H13 N O4 FORMUL 2 MH6 C3 H5 N O3 FORMUL 2 NH2 H2 N HELIX 1 1 GLY A 25 GLN A 30 1 6 HELIX 2 2 ASN A 34 THR A 46 1 13 HELIX 3 3 PRO A 74 GLY A 84 1 11 HELIX 4 4 ARG A 102 MET A 113 1 12 HELIX 5 5 PRO A 114 LEU A 116 5 3 HELIX 6 6 SER A 120 LYS A 133 1 14 SHEET 1 AA 3 ILE A 9 PRO A 14 0 SHEET 2 AA 3 ILE A 53 VAL A 60 -1 O LEU A 54 N LEU A 13 SHEET 3 AA 3 PHE A 66 ILE A 70 -1 O THR A 67 N THR A 59 SHEET 1 AB 2 GLY A 98 THR A 101 0 SHEET 2 AB 2 ILE A 137 VAL A 140 1 O GLU A 138 N VAL A 100 LINK C11 QUA B 0 OG1 THR B 12 1555 1555 1.33 LINK C7 QUA B 0 N ILE B 1 1555 1555 1.50 LINK C ALA B 2 N DHA B 3 1555 1555 1.38 LINK C DHA B 3 N ALA B 4 1555 1555 1.35 LINK C SER B 5 SG BB9 B 6 1555 1555 1.75 LINK CA SER B 5 C BB9 B 13 1555 1555 1.58 LINK CB SER B 5 CB MH6 B 14 1555 1555 1.52 LINK C SER B 5 N BB9 B 6 1555 1555 1.31 LINK C BB9 B 6 N THR B 7 1555 1555 1.32 LINK C THR B 7 N DBU B 8 1555 1555 1.35 LINK C DBU B 8 N DCY B 9 1555 1555 1.29 LINK C DBU B 8 SG DCY B 9 1555 1555 1.75 LINK C DCY B 9 N TS9 B 10 1555 1555 1.33 LINK C TS9 B 10 SG BB9 B 11 1555 1555 1.75 LINK C TS9 B 10 N BB9 B 11 1555 1555 1.28 LINK C BB9 B 11 N THR B 12 1555 1555 1.36 LINK C THR B 12 SG BB9 B 13 1555 1555 1.71 LINK C THR B 12 N BB9 B 13 1555 1555 1.29 LINK C BB9 B 13 N MH6 B 14 1555 1555 1.47 LINK C MH6 B 14 SG BB9 B 15 1555 1555 1.65 LINK C MH6 B 14 N BB9 B 15 1555 1555 1.30 LINK C BB9 B 15 N DHA B 16 1555 1555 1.38 LINK C DHA B 16 N DHA B 17 1555 1555 1.23 LINK C DHA B 17 N NH2 B 18 1555 1555 1.35 SITE 1 AC1 4 PRO A 22 A C1067 G C1068 A C1095 CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 1.000000 0.000000 0.000000 0.00000 SCALE2 0.000000 1.000000 0.000000 0.00000 SCALE3 0.000000 0.000000 1.000000 0.00000